Ex vivo evaluation of Newcastle disease virus to enhance natural killer cell function against acute myeloid leukemia cells Authors: Shima Tavoosi, Soheila Rahgozar, Mohammad Ahmadvand, Mostafa Jarahian, Kayhan Azadmanesh Published: 2026 ABSTRACT Natural killer (NK) cells are promising for adoptive cell therapy in hematological malignancies due to their ability to target tumors and tolerate HLA mismatch. However, their effectiveness is often limited by tumor immune evasion. The aim of this study was to investigate whether infection of AML cells with a non-lytic strain of Newcastle Disease Virus (NDV) can enhance NK cell-mediated cytotoxicity ex-vivo, as a preclinical proof-of-concept for potential sensitization strategies in AML immunotherapy. In the present study, AML cell lines and primary cells derived from newly diagnosed and relapsed/refractory patients were infected with the non-lytic NDV strain Ulster. Following infection, AML cells were co-cultured with NK cells at different Effector-to-Target ratios. Anti-tumor activity of NK cells was assessed by flow cytometry (CFSE/PI staining), lactate dehydrogenase release, and IFN-γ, perforin and granzyme B production. Our results showed that NDV infection of AML cells led to surface expression of viral hemagglutinin-neuraminidase, a danger signal and ligand for NK cell activating receptors. This, in turn, stimulated the specific cytotoxicity response of NK cells against AML cells and significantly elicited IFN-γ production as well as perforin and granzyme B secretion by activated NK cells. To the best of our knowledge, this is the first study demonstrating the potential of cancer immunotherapy through NDV infection of AML cells to enhance NK cell activation and cytotoxicity. Our findings could provide a rationale for a sequential therapeutic strategy in which NDV is administered in vivo to sensitize leukemic blasts, followed by adoptive transfer of ex vivo expanded NK cells to maximize anti-leukemic efficacy.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-56211-3. Introduction Acute myeloid leukemia (AML) is a phenotypically and genetically heterogeneous aggressive hematological malignancy that represents the most common form of acute leukemia in adults. It is mainly characterized by the uncontrolled proliferation of immature myeloid cells, known as blasts1. The most common approaches employed for treating various forms of AML include chemotherapy sometimes along with hematopoietic stem cell transplantation and targeted therapy drugs2. Despite considerable improvements in AML therapy over recent decades, the issues of refractory or relapsed (r/r) cases remain the most formidable challenge and are the leading cause of mortality among patients3,4. Therefore, the development of new treatment options is crucial for enhancing outcomes in AML. Recently, cell-based immunotherapy has emerged as a promising approach that aims to boost the effectiveness of existing treatments for AML5. NK cells are a key component of the innate immune system, making up approximately 5–20% of the circulating lymphocytes in humans. They play a crucial role in recognizing and eliminating virally infected or transformed cells without the need for prior sensitization6. Unlike T and B cells, which generate antigen receptors via gene rearrangements, NK cells express two distinct types of germline-encoding receptors and their activation is mediated through the incorporated balance of signaling by these activating and inhibitory receptors7. In AML patients, the correlation between impaired NK cell activity and an elevated risk of cancer is reported, suggesting a major role for NK cells in tumor suppression8,9. Moreover, in allogeneic stem cell transplantation, NK cells have been shown to mediate graft-versus-leukemia immunity towards recipient tumor cells without attacking normal tissues, preventing graft-versus-host disease. Due to the unique capacity of NK cells, they are being studied in adoptive cell therapy for AML10,11. While these therapies show overall clinical benefit, their effectiveness is limited by tumor immune evasion mechanisms that lead to an exhausted NK cell phenotype12,13. Therefore, strategies with higher tumor selectivity and more immunogenic properties to prevent NK cell exhaustion and restore their cytotoxic functions are urgently needed14. Newcastle disease virus (NDV) is a naturally modified, non-human avian paramyxovirus 1 (APMV-1) virus that exhibits an ability to replicate effectively in human cancer cells. NDV comprises various strains that differ in virulence, among which lentogenic strains are characterized by low pathogenicity. These strains are generally considered non-lytic, as they do not induce direct cell lysis but can still initiate a single round of viral replication within cancer cells15. NDV has a single-stranded, non-segmented, negative-sense RNA genome that encodes six genes producing at least eight proteins, including hemagglutinin-neuraminidase (HN). HN is a key multifunctional glycoprotein that enables the virus to attach to host cells, activate membrane fusion for viral entry, and facilitate release of new viral particles through its neuraminidase activity. This protein, highly expressed on the surface of NDV-infected tumor cells, has emerged as a promising anticancer agent, primarily due to its strong immunostimulatory effect, especially in activating NK cells16–18. The natural cytotoxicity receptors (NCR) NKp30, NKp44, and NKp46 are Ig-like transmembrane proteins, play an important role in antitumor and antiviral activities of NK cells19. HN proteins of NDV Ulster serve as activating ligand structures for NKp44 and NKp46 receptors in such a way that blocking HN with anti-HN antibodies leads to a reduction in NK cell activity20. Furthermore the direct molecular interaction of activating receptors NKp46 and NKp44 and their ligands (HN) on tumor cells promote signal transduction and NK cell activation via immunoreceptor tyrosine-based activation motifs-linked signaling chains, specifically CD3 ζ for NKp46 and DAP12 for NKp4421. In this study, we present, evidence that the expression of ligand structures (HN) for activating NK cell receptors (NKP44, NKP46) on NDV-infected tumor cells (AML cell lines and AML Primary cells) leads to enhanced secretion of NK cell effector molecules (IFN-γ, Granzyme B, and Perforin) by NK cells and increased susceptibility of infected tumor cells to NK cells-induced lysis (Fig. 1). Fig. 1Schematic representation of the experimental design evaluating the effects of NDV-infected AML cells on NK cell-mediated cytotoxicity against AML targets. Schematic representation of the experimental design evaluating the effects of NDV-infected AML cells on NK cell-mediated cytotoxicity against AML targets. Materials and methods Cell lines Two acute myeloid leukemia cell lines, KG1a and U937, were provided from the National Cell Bank of the Pasteur Institute of Iran and cultured in RPMI 1640 medium (Biosera, France) supplemented with 10% FBS (Gibco). Additionally, irradiated (100 Gy) modified K562 cells expressing 4-1BB ligand (BBL) were obtained from Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, and maintained in RPMI 1640 medium supplemented with 10% FBS and penicillin/ streptomycin. All cells were incubated at 37 ◦C, 5% CO2, and 95% humidity. Preparation and characterization of isolated NK cells Whole blood (20 mL) was collected from healthy individuals through intravenous sampling using blood collection syringes and EDTA-containing tubes. All experimental procedures received approval from the Ethics Committee of the University of Isfahan (agreement number IR.UI.REC.1402.105). Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using a density-gradient method (Ficoll-Histopaque; Sigma). NK cells were enriched from PBMC by negative selection using magnetic beads according to the manufacturer’s protocol (Miltenyi Biotec, Germany). The purity of the NK cells derived from peripheral blood (PB-NK) was evaluated by quantitatively measuring the ratios of CD3−and CD56+ markers through flow cytometry (CyFlow, Partec, Germany). Briefly, a total of 1 × 105 cells were collected, washed with phosphate-buffered saline (PBS), and stained with fluorochrome-conjugated antibodies (CD56−PE and CD3−FITC, BioLegend, USA) for 20 min at room temperature in the dark. After washing, the proportion of labeled cells was analyzed using a flow cytometry instrument (CyFlow, Partec, Germany). The gating strategy employed for the analysis, including sequential exclusion of debris and doublets followed by identification of CD3 − CD56+ NK cells, is detailed in the Supplementary Information (Supplementary Fig. 3). For NK cell expansion, 2 × 106 purified CD3−CD56+ NK cells were stimulated on day 0 with irradiated (100 Gy) modified K562 cells that express the 4-1BB ligand at a ratio of 20:1 feeder cells to NK cells. The culture was supplemented with recombinant human IL-2 (500 U/mL; Miltenyi Biotec, Inc., San Diego, CA), IL-15 (10 ng/mL; Miltenyi Biotec, Inc., San Diego, CA), and 10% fetal bovine serum (FBS) in RPMI 1640 medium (Biosera, France). The NK cells were maintained in fresh medium supplemented with 500 U/mL of IL-2 and 10 ng/mL of IL-15 every three days in a humidified incubator at 37 °C with 5% CO2 until they reached the desired cell concentration for 14–21 days. Patient characteristics and sample collection Peripheral blood samples were obtained from all participants following written informed consent and with approval from the Ethics Committee of the University of Isfahan (agreement number IR.UI.REC.1402.105). All methods were performed in accordance with the relevant guidelines and regulations. Blood samples from nine newly diagnosed AML patients with different AML subtypes, excluding M3, were collected at Shariati Hospital, Tehran. None of the patients had received any treatment prior to sample collection. Blast percentages were determined in the clinical laboratory using flow cytometric immunophenotyping. Leukemic blasts were identified based on the expression of myeloid and progenitor markers including CD13, CD33, CD34, CD117, and HLA-DR. Only patient samples with a blast percentage greater than 80% were included in the study (Table 1) to ensure a high proportion of leukemic cells in downstream experiments. In addition, primary AML cells from two patients in the relapse/refractory (R/R) phase with a high blast percentage (~ 60%) were also included. Peripheral blood mononuclear cells (PBMCs) were isolated from patient blood samples using Ficoll density gradient centrifugation and subsequently cultured in RPMI-1640 medium (Biosera, France) supplemented with 10% fetal bovine serum (FBS) for further experiments, including NDV infection assays. Table 1Patient characteristic.Patient IDAge (years)SexSubtype of AMLP132MM1P250FM4P364FM2P446MM4P571FM1P638MM5P749MM2P856MM4P969FM6R/R P132MM1R/R P248FM2F=Female, M=Male. Table 1Patient characteristic.Patient IDAge (years)SexSubtype of AMLP132MM1P250FM4P364FM2P446MM4P571FM1P638MM5P749MM2P856MM4P969FM6R/R P132MM1R/R P248FM2F=Female, M=Male. Patient characteristic. F=Female, M=Male. NDV purification and titration The non-lytic NDV strain Ulster was prepared and inoculated (0.1 mL of the NDV stock) into an allantoic cavity of 10-day-old embryonated specific pathogens-free (SPF) eggs. The inoculated eggs were incubated at 37 °C with 60% humidity for five days. After this incubation period, the allantoic fluid was harvested followed by centrifuging (3,000 g for 5 min,4 C) to remove debris. The NDV was then extracted from the allantoic fluid and further purified through high-speed centrifugation at 30,000 g for 1 h at 4 °C. The purified virus was re-suspended in phosphate buffered saline containing 2% FBS at pH 7.4 and, subsequently, titrated using hemagglutination assay in which 1 hemagglutination unit (HU) is defined as the lowest virus concentration leading to visible chicken erythrocyte agglutination. Finally, the resulting virus was stored at -70 °C for future analysis. Virus infection Following the washing of target cells (KG1a, U937 cell lines and PBMC sample of AML patients), the cells were re-suspended in FBS-free media at the concentration of 106 cells/mL. Then 100 HU of NDV-Ulster viruses were added to each one million cells in this medium and incubated at 37 °C for 2 h with gentle shaking every 20 min. After infection, cells were washed twice to remove excess viral particles and then incubated for 18–20 h to allow surface expression of the viral HN glycoprotein on the tumor cells. Post infection validation of HN expression using flow cytometry After 18–20 h, 1 × 105 cells were harvested, washed once in fluorescence-activated cell sorter (FACS) buffer and subsequently incubated with 1 ug/mL anti-HN monoclonal antibody (Abcam) for 1 h on ice. Following this incubation, and a wash with FACS buffer (400 g, 5 min, 4 °C), cells were stained with FITC-conjugated secondary antibody (Goat Anti-Human FITC conjugate, Abcam) for 30 min on ice. Finally, the cells were washed twice and re-suspended in FACS buffer for analysis by flow cytometry (CyFlow, Partec, Germany). A Flow cytometry-based cytotoxicity assay The cytotoxicity of expanded NK cells against target tumor cells was measured by a flow cytometry-based assay that involved staining target cells with carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen). In this procedure, target cells were labeled with 1 μm CFSE in 1 mL of PBS for 10 min at 37 °C. Afterward, the cells underwent three washes with complete medium containing 10% FBS to stop the labeling reaction. After a 2 h infection with NDV at a concentration of 100 HU/ per million cells, 50,000 CFSE-labeled target cells were washed and placed in each well of a 96-well round-bottom plate (Thermo Fisher). 18–20 h later, the CFSE-labeled NDV-infected and un-infected target cells were co-cultured with effector cells (NK cells) at an Effector: Target (E: T) ratio of 1:1 and 10:1 for 10–12 h in 96-well round bottom plate with a total volume of 200 µl. The Co-cultured cells were gently mixed and centrifuged at 200 g for 2 min to facilitate cell contact. After the incubation period, the mixed cells were transferred to FACS tubes and treated with 1 µl of 1 mg/mL propidium iodide (PI) (Sigma) in the dark for 5 min and were subsequently measured by flow cytometry (CyFlow, Partec, Germany). The comprehensive flow cytometric analysis, along with the corresponding gating strategy, is shown in Supplementary Fig. 4. Analysis of IFN-γ, Granzyme B, and perforin secretion by ELISA Secreted levels of IFN-γ and cytotoxic granules (granzyme B, perforin) released by activated NK cells were quantified by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s protocols for the Human ELISA Kits (MabTech). Briefly, the tumor cells were infected with the NDV strain Ulster (100HU/106 cells) for 2 h. Both infected and un-infected tumor cells were plated in a 96-well round-bottom plate at a density of 50,000 cells per well and incubated at 37 °C in a humidified environment with 5% CO2 for 18 to 20 h. The next day, these target cells were co-cultured with NK cells at 37 °C, using effector-to-target ratios of 1:1 and 10:1. After a 10–12 h incubation period, the plate was centrifuged (120 g, 10 min), and the supernatant was collected to assess the levels of secreted IFN-γ, Granzyme B, Perforin. Lactate dehydrogenase (LDH) release assay NK cell cytotoxicity against tumor cells was assessed using lactate dehydrogenase release assay (LDH). The infected (100HU/106 cells) and un-infected tumor Cells (50,000 cells) were cultured in 96well round bottom plate and after an incubation period of 18–20 h, NK cells were added at different ratios (1:1 and 10:1 effector to target cells). Following a 10–12 h co-culture period, 50 µl aliquot of the media was taken and the LDH assay was done according to manufacturer’s guidelines (Roche, Switzerland). NK cytotoxicity was analyzed as target lysis.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:Cytotoxicity\:\left(\%\right)=\frac{sample\:LDH-Effector\:spontauneous-Target\:spontaneous}{(Target\:Maximum-Target\:spontanous\:)}\:\times\:100\:$$\end{document} Statistical analysis All statistical analyses were performed using the Graph-Pad Prism 10 software (GraphPad Software, Inc.,La Jolla, CA, USA). Graphical data are presented as means ± standard deviation. Statistical analysis was performed using t-test for comparisons between the two groups. For comparisons involving three or more groups, one-way ANOVA was applied. To assess overall differences among patient population groups, two-way ANOVA was used followed by Tukey’s multiple comparisons test. P values less than 0.05 were considered significant. Flow cytometry analysis was performed using FlowJo software, version 10. Results HN expression on target cells following NDV infection To assess HN surface expression on NDV-infected AML cells, two cell lines (KG1a and U937) along with AML blasts from four patients were infected with the Ulster strain of NDV (100 HU/106 cells) for 2 h. After 18–20 h, HN expression was evaluated by flow cytometry using an anti-HN monoclonal antibody followed by a FITC-conjugated secondary antibody. The results demonstrated efficient NDV infection, as indicated by a high proportion of HN-positive cells in both AML cell lines and patient’s-samples (Fig. 2). Fig. 2HN surface expression in AML cells after NDV infection. KG1a (A), U937 (B) cell lines, along with primary AML blasts (C–F), were infected with the NDV Ulster strain (100 HU per 106 cells) for 2 h. After 18–20 h, cells were stained with an antiHN monoclonal antibody followed by a FITCconjugated secondary antibody and analyzed by flow cytometry. Representative dot plots illustrate HN expression detected in the FITC channel in infected cells compared with their respective controls. (G) Control staining includes uninfected cells and a secondary antibody–only condition. (H) The bar graph summarizes the percentage of HNpositive cells in the analyzed samples. ****p ≤ 0.0001. HN surface expression in AML cells after NDV infection. KG1a (A), U937 (B) cell lines, along with primary AML blasts (C–F), were infected with the NDV Ulster strain (100 HU per 106 cells) for 2 h. After 18–20 h, cells were stained with an antiHN monoclonal antibody followed by a FITCconjugated secondary antibody and analyzed by flow cytometry. Representative dot plots illustrate HN expression detected in the FITC channel in infected cells compared with their respective controls. (G) Control staining includes uninfected cells and a secondary antibody–only condition. (H) The bar graph summarizes the percentage of HNpositive cells in the analyzed samples. ****p ≤ 0.0001. Expansion of NK cells using genetically modified K562 cells expressing 4-1BB ligand (4-1BBL) Stable surface expression of 4-1BB ligand on modified K562 cells as feeder cell was confirmed by flow cytometry prior to their use in NK cell expansion (Supplementary Fig. 3A). Human primary NK cells were isolated from peripheral blood lymphocytes of healthy donors by using the NK cell negative isolation kit and stained with fluorochrome-labeled antibodies (CD56-PE and CD3-FITC). At baseline (Day 0), the analysis of flow cytometry revealed that the frequency of CD56 + CD3− cells in the isolated PB-NK cell population was 89.5% (Figure. 3A). This high initial purity was achieved following MACS isolation. While after culturing with modified K562 in RPMI 1640 complete media supplemented with IL-2 (500 U/mL), IL-15 (10 ng/mL) the purity of the NK cell population increased to 95.4% on day 21 (Fig. 3B). The morphological changes during the expansion period were monitored using phase-contrast microscopy. By Day 7, small clusters of NK cells began to form, which progressively increased in size and density by Day 14 and Day 21 (Figure. 3B). These large, dense clusters are characteristic of robust NK cell activation and rapid proliferation. Regarding NK cell proliferation kinetics, we observed distinct patterns based on the feeder cell type. NK cell expansion was comparatively limited when co-cultured with unmodified K562 feeder cells, resulting in approximately a 15-fold increase over 21 days. In contrast, co-culture with genetically modified K562 expressing 4-1BBL markedly enhanced proliferation to nearly 600-fold at day 21(Supplementary Fig. 3B). This dramatic difference highlights the critical role of 4-1BBL signaling in driving robust NK cell expansion. Fig. 3Phenotypic characterization and morphological assessment of expanded NK cells. (A) Representative flow cytometry dot plots of CD3⁻CD56⁺ NK cells isolated from peripheral blood mononuclear cells (PBMCs) at Day0 and following expansion with genetically modified K562 feeder cells. (B) Representative phase-contrast microscopy images showing NK cell morphology and cluster formation during ex vivo culture at Days 7, 14, and 21 following co---15. Phenotypic characterization and morphological assessment of expanded NK cells. (A) Representative flow cytometry dot plots of CD3⁻CD56⁺ NK cells isolated from peripheral blood mononuclear cells (PBMCs) at Day0 and following expansion with genetically modified K562 feeder cells. (B) Representative phase-contrast microscopy images showing NK cell morphology and cluster formation during ex vivo culture at Days 7, 14, and 21 following co---15. Enhanced NK-mediated lysis against NDV-infected target cell lines To evaluate whether NDV infection (Ulster strain) enhances the cytotoxic activity of NK cells against AML cells, two cell lines, U937 and KG1a, were used as target cells. Ex vivo expanded NK cells were used as effector cells. NDV-infected (Ulster strain, 100 HU per 106 tumor cells) and un-infected cells were labeled with CFSE and seeded into 96-well plates. Then, NK cells were added at two different effector-to-target (E: T) ratios (1:1 and 10:1). After incubation at 37 °C for 10–12 h, cells were stained with PI and analyzed by flow cytometry. Cytotoxicity was determined based on the percentage of CFSE⁺/PI⁺ cells. Remarkable cytotoxicity of NK cells against KG1a and U937 cell lines was observed in a dose-dependent manner. Although NDV alone did not induce tumor cell death, it synergistically enhanced NK cell-mediated cytotoxicity, particularly at higher effector-to-target ratios, making NDV-infected target cells significantly more susceptible to NK cell killing compared to un-infected cells (Fig. 4). The U937 cell line showed a greater response, with cytotoxicity reaching approximately 48.1% ± 1.06 at the highest E: T ratio, whereas KG1a cells exhibited about 27.35% ± 0.8 lysis under the same conditions. Fig. 4Assessment of NK cell cytotoxicity against AML cell lines. NK cells (effectors) were co-cultured with CFSE-labeled AML cells (KG1a and U937; targets) at varying effector-to-target (E: T) ratios, with or without prior NDV infection. After 10–12 h of co-culture, the proportion of PI⁺ cells within the CFSE⁺ target population was measured by flow cytometry to evaluate cytotoxicity. (A) Representative dot plots showing CFSE⁺/PI⁺ double-positive cells in KG1a and U937 lines. (B) Quantitative comparison of NK cell-mediated cytotoxicity at different E: T ratios in NDV-infected versus uninfected cells. Data are presented as mean ± SD. **P ≤ 0.01; ***P ≤ 0.001; ****p ≤ 0.0001. Assessment of NK cell cytotoxicity against AML cell lines. NK cells (effectors) were co-cultured with CFSE-labeled AML cells (KG1a and U937; targets) at varying effector-to-target (E: T) ratios, with or without prior NDV infection. After 10–12 h of co-culture, the proportion of PI⁺ cells within the CFSE⁺ target population was measured by flow cytometry to evaluate cytotoxicity. (A) Representative dot plots showing CFSE⁺/PI⁺ double-positive cells in KG1a and U937 lines. (B) Quantitative comparison of NK cell-mediated cytotoxicity at different E: T ratios in NDV-infected versus uninfected cells. Data are presented as mean ± SD. **P ≤ 0.01; ***P ≤ 0.001; ****p ≤ 0.0001. Enhanced IFN-γ, granzyme B, and perforin secretion by NK cells in response to NDV-infected AML cell lines Fig. 5Production of IFN-γ, Granzyme B, and Perforin by activated NK cells. NK cells were co-cultured with NDV infected and un-infected KG1a (A) and U937 (B) at different ratios (1:1, 10:1). After 10–12 h, the supernatant was collected and IFNg, granzyme B, and perforin production were evaluated by ELISA. P values less ≤ 0.05 were considered statistically significant. * P value ≤ 0.05, ** P value ≤ 0.01, *** P value ≤ 0.001 ****p ≤ 0.0001. Production of IFN-γ, Granzyme B, and Perforin by activated NK cells. NK cells were co-cultured with NDV infected and un-infected KG1a (A) and U937 (B) at different ratios (1:1, 10:1). After 10–12 h, the supernatant was collected and IFNg, granzyme B, and perforin production were evaluated by ELISA. P values less ≤ 0.05 were considered statistically significant. * P value ≤ 0.05, ** P value ≤ 0.01, *** P value ≤ 0.001 ****p ≤ 0.0001. To assess whether NDV infection directly enhances NK cell function through increased NK cell effector molecules secretion, two AML cell lines (KG1a and U937) were infected with the NDV Ulster strain. After 18–20 h, both infected and un-infected cells were co-cultured with ex vivo expanded NK cells at effector-to-target (E: T) ratios of 1:1 and 10:1. Following 10–12 h of co-culture, levels of IFN-γ and cytotoxic proteins (granzyme B, perforin) in the culture supernatant were measured by ELISA. As shown in Fig. 5, IFN-γ (A, D), granzyme B (B, E) and perforin (C, F) production increased with a higher NK cell ratio in both infected and un-infected groups. However, NDV infection markedly amplified this response. NDV-infected AML cells induced significantly stronger NK cell responses compared to uninfected cells. In both cell lines, NDV infection enhanced NK cell activation, as demonstrated by elevated IFN-γ, granzyme B and perforin secretion. Increased LDH release indicates enhanced NK cell-mediated cytotoxicity against NDV-infected AML cells To further assess NK cell-mediated cytotoxicity, cell lysis was determined by the release of LDH, a cytosolic enzyme, which can be secreted by necrotic cells into culture medium. The frequency of LDH is directly associated with the cytotoxicity of NK cells. Expanded NK cells were co-cultured with NDV-infected or un-infected AML cell lines (KG1a and U937) at different effector-to-target (E: T) ratios (1:1 and 10:1). After 10–12 h, LDH levels in the supernatant were analyzed. Although the difference in LDH release between NDV-infected and un-infected groups in the absence of NK cells was not statistically significant in both cell lines (p > 0.05), NK cell–mediated cytotoxicity increased proportionally with rising effector-to-target (E: T) ratios. Furthermore, this effect was significantly enhanced by NDV pre-treatment, which further amplified NK cell–induced tumor cell lysis and subsequently increased LDH release. As shown in Fig. 6, in the absence of NDV, cell lysis increased from 6.5% ± 0.71 to 10.5% ± 0.73 in KG1a cells and from 10% ± 2.8 to 17% ± 1.4 in U937 cells when the E: T ratio increased from 1:1 to 10:1. NDV pre-treatment further enhanced cytotoxicity, with LDH release reaching 23% ± 1.5 in KG1a cells and 28.5% ± 0.7 in U937 cells at an E: T ratio of 10:1 (Fig. 6). These findings support the role of NDV in amplifying NK cell-mediated lysis of AML cells in a dose-dependent manner. Fig. 6Comparison of NK cells cytotoxicity against AML cell lines by LDH release assay. The NDV-infected and un-infected KG1a (A) and U937 (B) cell lines were co-cultured with NK Cells at different E: T. After 10–12 h the supernatant collected and Specific cell lysis evaluated by LDH assay. P values less ≤ 0.05 were considered statistically significant. * P value ≤ 0.05, ** P value ≤ 0.01, *** P value ≤ 0.001 ****p ≤ 0.0001. Comparison of NK cells cytotoxicity against AML cell lines by LDH release assay. The NDV-infected and un-infected KG1a (A) and U937 (B) cell lines were co-cultured with NK Cells at different E: T. After 10–12 h the supernatant collected and Specific cell lysis evaluated by LDH assay. P values less ≤ 0.05 were considered statistically significant. * P value ≤ 0.05, ** P value ≤ 0.01, *** P value ≤ 0.001 ****p ≤ 0.0001. NK cell function against AML blasts of newly diagnosed patients after infection with NDV To assess the sensitivity of AML blasts of patients to NK cell-mediated cytotoxicity, samples from nine newly diagnosed patients were co-cultured with ex vivo expanded NK cells. CFSE-labeled blasts, either NDV-infected or un-infected, were incubated with NK cells at E: T ratios of 1:1 and 10:1 for 10–12 h. Cytotoxicity was measured by flow cytometry (CFSE⁺/PI⁺ cells), and culture supernatant was collected to assess LDH release and IFN-γ secretion. The results revealed substantial inter-patient variability in NK cell-mediated killing, yet in all cases, cytotoxicity increased with higher E: T ratios, regardless of NDV infection status. Interestingly, unlike the AML cell lines, the non-lytic NDV strain alone induced partial cell death in blasts isolated from some patients (Fig. 7A). However, the mean cytotoxic effect of NDV treatment alone, compared to un-infected control, was not statistically significant (p = 0.1; Fig. 7D). When comparing NK cell cytotoxicity with and without prior NDV infection of target cells, a significant enhancement in cytotoxic activity was observed in NDV-infected groups at both E: T ratios. This trend was consistently supported by LDH release assay, which showed that specific cell lysis correlated with increasing NK cell numbers, and that LDH levels were markedly higher in NDV-infected compared to un-infected groups (Fig. 7B,E), confirming the enhanced cytotoxic potential of NK cells following NDV sensitization of AML blasts. Similarly, IFN-γ secretion was markedly higher in NDV-infected groups, further supporting the enhanced activation and cytotoxic potential of NK cells following NDV sensitization (Fig. 7C,F). Fig. 7Susceptibility of blasts derived from 9 newly diagnosed AML patients to expanded NK cells cytotoxicity. Cytotoxicity of NK against primary AML cells by Flow cytometry (A,D) Specific cell lysis represented by LDH concentrations (B,E) IFN-γ secretion test by ELISA (C,F) in 1:1 and 10:1 E: T ratios in presence and absence of NDV infection. In (D–F), each symbol represents the mea of triplicate measurements of every patient. P values less ≤ 0.05 were considered statistically significant. *P value ≤ 0.05, **P value ≤ 0.01, ***P value ≤ 0.001 ****p ≤ 0.0001. Susceptibility of blasts derived from 9 newly diagnosed AML patients to expanded NK cells cytotoxicity. Cytotoxicity of NK against primary AML cells by Flow cytometry (A,D) Specific cell lysis represented by LDH concentrations (B,E) IFN-γ secretion test by ELISA (C,F) in 1:1 and 10:1 E: T ratios in presence and absence of NDV infection. In (D–F), each symbol represents the mea of triplicate measurements of every patient. P values less ≤ 0.05 were considered statistically significant. *P value ≤ 0.05, **P value ≤ 0.01, ***P value ≤ 0.001 ****p ≤ 0.0001. Enhanced NK cell function against AML blasts of relapsed/refractory (R/R) patients after infection with NDV To evaluating the NK cells effect on drug resistant AML blasts, AML blasts were isolated from two patients with relapsed/refractory (R/R) AML during the relapse phase. Primary cells were co-cultured with NK cells 10-12-hours post-infection in 1:1 and 10:1 E: T ratios. Flow cytometry and IFN-γ secretion results showed a significant higher cytotoxicity in NK cells targeting NDV-infected cells compered to un-infected cells in a dose dependent manner. Furthermore, NDV alone induced AML blasts lysis only in patient 1, independent of NK cell activity. However, combining NDV-infected blasts with NK cells resulted in enhanced NK cell cytotoxicity at both E: T ratios in samples from two patients (Fig. 8). Fig. 8Evaluation of the sensitivity of AML blasts from two refractory/relapsed patients to the cytotoxic effects of expanded NK cells. NK cell-mediated cytotoxicity against primary AML blasts was analyzed by flow cytometry (A,B). IFN-γ production by NK cells was determined via ELISA (B, right panels) at effector-to-target ratios of 1:1 and 10:1, both with and without Newcastle Disease Virus (NDV) infection. Data in represent the mean ± SD of triplicate samples per patient. Statistical significance was set at P ≤ 0.05 (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns = not significant). Evaluation of the sensitivity of AML blasts from two refractory/relapsed patients to the cytotoxic effects of expanded NK cells. NK cell-mediated cytotoxicity against primary AML blasts was analyzed by flow cytometry (A,B). IFN-γ production by NK cells was determined via ELISA (B, right panels) at effector-to-target ratios of 1:1 and 10:1, both with and without Newcastle Disease Virus (NDV) infection. Data in represent the mean ± SD of triplicate samples per patient. Statistical significance was set at P ≤ 0.05 (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ns = not significant). Discussion This study presents the first evidence supporting the potential of NDV-mediated infection of AML cells as a strategy for activating NK cells in the context of cancer immunotherapy. Our findings showed that NDV infection significantly improved NK cell cytotoxicity and IFN-γ secretion in both AML cell lines and primary AML blasts isolated from patients. Ex vivo expansion of NK cells is crucial for their clinical application. Commonly, cytokines like IL-2 and IL-15 are used to stimulate NK cells proliferation via shared signaling pathways such as PI3K/AKT/mTOR22. For optimal expansion, additional co-stimulatory signals are required. Various cell types have been used for this, but genetically engineered K562 cells expressing co-stimulatory molecules offer more efficient NK cells expansion23,24. Using genetically engineered K562 cells expressing 4-1BBL in combination with IL-2 and IL-15, we successfully expanded NK cells with potent cytotoxic activity. Although both autologous and allogeneic NK cells have been safely utilized in cancer therapies25, it is well established that NK-mediated cytolytic activity is significantly impaired in AML patients26–28. The use of NK cells derived from healthy donors provides an off-the-shelf product with enhanced anti-tumor activity primarily attributable to KIR-ligand mismatch, while also circumventing the functional impairments commonly observed in patient-derived NK cells29,30. Results of the LDH assay and flow cytometry (CFSE/PI cells) analysis demonstrated effective cytotoxicity of healthy donor-derived NK cells against AML cell lines (KG1a and U937) as well as primary blasts from both newly diagnosed and relapsed/refractory (R/R) AML patients. Nevertheless, AML cells employ various immune evasion strategies, including the downregulation of activating ligands and the upregulation of inhibitory signals, to resist NK cell mediated cytotoxicity12,26. Our findings confirm previous studies showing that AML cells, particularly drug-resistant cell lines such as KG1a, exhibit less sensitivity to NK cell-mediated cytotoxicity31,32. While U937 cell line exhibits greater sensitivity to NK cells compared to the KG1a cell line. Additionally, the cytotoxicity of NK cells varied against AML blasts obtained from different AML patients. This variability highlights the challenge of AML heterogeneity in immunotherapy and the need for strategies to overcome immune evasion. To enhance the anti-tumor capabilities of NK cells, a comprehensive set of approaches, including, monoclonal antibodies, non-viral gene silencing methods, NK cell engagers (BiKEs and TriKEs) and genetically engineer NK cells (CAR-NK) are being investigated which each of them has its complexities and costs14,33. Another intervention to activate the immune system against cancer tumors might be the application of several oncolytic viruses such as Herpes simplex34,35, measles36 and the non-lytic strain of Newcastle Disease Virus37. While numerous oncolytic viruses are currently undergoing pre-clinical and clinical evaluation for oncological applications, oncolytic virotherapy is associated with several limitations. One major challenge is the formation of neutralizing antibodies by the host immune system, which may hinder effective viral delivery to malignant tissues and reduce therapeutic efficacy. Furthermore, some oncolytic viruses may infect non-malignant cells, potentially triggering off-target immune responses against healthy tissues38,39. Accordingly, in the present study we utilized NDV, a non-pathogenic virus in humans that has demonstrated a strong tumor-selective tropism. NDV preferentially replicates in malignant cell due to defects in antiviral type I interferon signaling pathways, whereas replication in normal human cells is effectively controlled by intact antiviral responses18,40–43. These characteristics contribute to its favorable safety profile and support its development as a promising ant-tumor agent capable of stimulating both local and systemic anti-tumor immune responses44,45. The HN protein of NDV binds specifically to sialic acid residues on the surface of tumor cells, and variations in the types and patterns of these sialic acids among different tumor cells contribute to their differential susceptibility to NDV infection and replication46,47.The AML cells are known to exhibit hyper-sialylation, with up to 40–60% higher levels of surface sialic acids compared to healthy hematopoietic cells48. This increased sialylation likely enhances their permissiveness to NDV. In our study, we observed that HN protein expression in NDV-infected AML cells reached approximately 70–90% at 16–18 h post-infection, levels comparable to those reported in established infected cell lines20. This finding further supports the notion that AML blasts exhibit high susceptibility to NDV, likely attributable to their elevated surface expression of sialic acid residues. Jarahian et al. previously demonstrated that the HN protein of NDV can directly engage and activate natural cytotoxicity receptors, specifically NKp44 and NKp46, on the surface of NK cells20. Although our study primarily focused on the role of HN, NDV infection may alter the surface molecular profile of tumor cells, thereby influencing NK cell recognition. These alterations may strengthen activating receptor engagement (such as NKG2D), improve immune synapse formation, or alternatively contribute to immune escape mechanisms18. In line with other studies, we showed enhanced NK cell activation, evidenced by elevated cytotoxicity, when co-cultured with NDV-infected AML cells20,49. Unlike lytic NDV strains, which undergo multiple rounds of replication and induce direct lysis of infected cancer cells, non-lytic strains such as Ulster are replication-limited to a single cycle and do not produce significant progeny virus then exert their antitumor effects through sustained immune activation and immunomodulation50. According to our results, NDV (Ulster) infection alone did not induce notable cytotoxicity in AML cell lines. However, a moderate degree of cell death was observed in primary AML blast samples from some patients following infection. This variability may be attributable to differences in type I interferon (IFN) signaling between individual patient samples. The NDV is known to replicate preferentially in cells with impaired IFN responses, whereas increased expression of interferon-stimulated genes (ISGs) can limit viral replication and reduce oncolytic efficacy51,52. Although NDV Ulster exhibited some direct tumoricidal activity, it significantly enhanced the cytotoxic efficacy of NK cells in a synergistic manner. Accordingly, in agreement with other studies, the same patterns of IFN-γ secretion by activated NK cells were also observed in our research53. Experimental findings indicate that NK cell production of IFN-γ can be stimulated by a short incubation period (4–24 h) with tumor cells54. However, recently, it was reported that CD56dim NK cells, known for their rapid IFN-γ production, reach peak secretion levels within 2 to 4 h after activation, while IFN-γ levels become undetectable after 16 h55. Our results demonstrated that 10–12 h following co-culture, NK cells exposed to NDV-infected tumor cells exhibited a marked increase in the secretion of IFN-γ and the cytotoxic effector molecules granzyme B and perforin compared with NK cells co-cultured with un-infected tumor cells. This enhanced secretory profile translated into potentiated NK cell-mediated anti-tumor activity. In addition, NK cell-derived IFN-γ promotes Th1 cell polarization and subsequent Cytotoxic-T-lymphocyte priming, thereby establishing a functional bridge between innate and adaptive antiviral immunity. Concurrently, granzyme B and perforin directly induce tumor cell apoptosis. Collectively, these finding indicate that NDV infection of tumor cells amplifies NK cell effector functions and strengthens both immediate cytotoxic responses and downstream adaptive immune activation20,56,57. In summary, our findings support the use of NDV (Ulster) as an immunomodulatory agent to increase NK cell function against AML cells. While NDV overcomes tumor-mediated immune evasion and improves NK cell cytotoxicity, future studies should explore NDV-based immunotherapy in larger cohorts. Additionally, combining NDV therapy with existing AML treatments, checkpoint inhibitors and NK cell engagers (BiKEs/TriKEs) could further enhance antitumor immunity. Limitations and future directions While our findings demonstrate that NDV enhances the cytotoxic function of NK cells in vitro, more comprehencive phenotypic and functional characterization is warranted to elucidate the underlying mechanisms. In particular, detailed analysis of NK-cell subsets (CD56^dim/CD56^bright), activation and degranulation markers (CD69, CD107a), Activating receptors (NKP44, NKP46), and inhibitory or exhaustion-associated receptors (NKG2A, PD-1, TIGIT) would further clarify the underlying mechanisms. Although previous studies suggest that the NDV-HN protein can engage NKp44 and NKp46, receptor-blocking or ligand-neutralization experiments were not performed in this study and would be essential to establish direct causality. Furthermore, the NK cells used in this study were derived from healthy donors, which may not fully reflect the functional heterogeneity or potential immune dysregulation observed in NK cells from patients with AML. Future studies incorporating patient-derived NK cells, as well as NK cells expanded under clinically relevant conditions such as cytokine-driven or feeder cell–based expansion systems, will be critical to better assess the translational applicability of these findings. In addition, longitudinal profiling of NK-cell activation and exhaustion markers under different expansion conditions would further delineate how NK-cell functional states influence NDV-mediated sensitization of AML blasts. NDV infection was performed in bulk PBMCs rather than purified leukemic blasts. However, the high blast proportion (> 80%) indicates that most infected cells were malignant. Consistent with prior reports showing preferential NDV replication in cancer cells due to impaired antiviral responses, this supports the validity of our approach. Nevertheless, future studies using purified blast populations and larger AML cohorts are needed to more precisely define the cellular specificity of NDV infection. Finally, in vivo validation using appropriate animal models, followed by early-phase clinical trials are necessary to confirm the safety, persistence, and antitumor efficacy of NDV, as well as its capacity to sustain NK cell function. Ongoing and future studies aim to address these aspects and to further support the translational potential of this therapeutic approach. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3